Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Prognostic role of minichromosome maintenance family in multiple myeloma

Cancer Gene Therapy volume 27, pages 819–829 (2020)Cite this article

Subjects

Abstract

Multiple myeloma (MM) is a plasma cell malignancy. The minichromosome maintenance (MCM) family involve in DNA replication and is vital in limiting replication in cell cycle. The prognostic role of MCMs in MM is still unclear. We took four independent GEO datasets to analyze the relationship between the expression of MCMs and myeloma progression and survival. The expression of MCMs showed an upward trend with myeloma progression in 205 patients. High MCM2/3/4/6/8 expression was associated with both poor EFS and OS (all p < 0.050). Multivariate analysis demonstrated that high MCM2 expression, B2M, and LDH were independent risk factors. Moreover, the combination of MCM2/B2M and MCM2/LDH was a better tool in prognostication. In conclusion, high MCM2 expression is an independent adverse prognostic factor and could be used as a prognostic biomarker in MM.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The expression level of MCMs in GSE13591 dataset of myeloma patients in different stages.
Fig. 2: Kaplan–Meier curves of event-free survival (EFS) and overall survival (OS) in GSE24080 dataset.
Fig. 3: The correlations between the expression levels of MCM members.
Fig. 4: Kaplan–Meier curves of event-free survival (EFS) and overall survival (OS) in GSE24080 dataset.

Similar content being viewed by others

References

  1. Renee E, Dipti T. Multiple myeloma: from diagnosis to treatment. Aust Fam Physician. 2013;42:684–8.

    Google Scholar 

  2. Multiple myeloma. Am Fam Physician. 2017;95:online.

  3. Fernandez de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013;27:780–91.

    Article  CAS  Google Scholar 

  4. Brigle K, Rogers B. Pathobiology and diagnosis of multiple myeloma. Semin Oncol Nurs. 2017;33:225–36.

    Article  Google Scholar 

  5. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.

    Article  Google Scholar 

  6. Forsburg SL. Eukaryotic MCM proteins: beyond replication initiation. Microbiol Mol Biol Rev. 2004;68:109–31.

    Article  CAS  Google Scholar 

  7. Tye BK. MCM proteins in DNA replication. Annu Rev Biochem. 1999;68:649–86.

    Article  CAS  Google Scholar 

  8. Freeman A, Morris LS, Mills AD, Stoeber K, Laskey RA, Williams GH, et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res. 1999;5:2121.

    CAS  PubMed  Google Scholar 

  9. Alison MR, Hunt T, Forbes SJ. Minichromosome maintenance (MCM) proteins may be pre-cancer markers. Gut. 2002;50:290–1.

    Article  CAS  Google Scholar 

  10. Kearsey SE, Labib K. MCM proteins: evolution, properties, and role in DNA replication. Biochim Biophys Acta. 1998;1398:113–36.

    Article  CAS  Google Scholar 

  11. Das M, Prasad SB, Yadav SS, Govardhan HB, Pandey LK, Singh S, et al. Over expression of minichromosome maintenance genes is clinically correlated to cervical carcinogenesis. PLoS ONE. 2013;8:e69607.

    Article  CAS  Google Scholar 

  12. Kwok HF, Zhang S-D, McCrudden CM, Yuen H-F, Ting K-P, Wen Q, et al. Prognostic significance of minichromosome maintenance proteins in breast cancer. Am J Cancer Res. 2015;5:52–71.

    CAS  PubMed  Google Scholar 

  13. Zhong H, Chen B, Neves H, Xing J, Ye Y, Lin Y, et al. Expression of minichromosome maintenance genes in renal cell carcinoma. Cancer Manag Res. 2017;9:637–47.

    Article  CAS  Google Scholar 

  14. Hua C, Zhao G, Li Y, Bie L. Minichromosome maintenance (MCM) family as potential diagnostic and prognostic tumor markers for human gliomas. BMC Cancer. 2014;14:526.

    Article  Google Scholar 

  15. Liu K, Kang M, Liao X, Wang R. Genome-wide investigation of the clinical significance and prospective molecular mechanism of minichromosome maintenance protein family genes in patients with lung adenocarcinoma. PLoS ONE. 2019;14:e0219467.

    Article  CAS  Google Scholar 

  16. Eissa S, Matboli M, Shehata HH, Essawy NO. MicroRNA-10b and minichromosome maintenance complex component 5 gene as prognostic biomarkers in breast cancer. Tumour Biol. 2015;36:4487–94.

    Article  CAS  Google Scholar 

  17. Mitsiades CS, Ocio EM, Pandiella A, Maiso P, Gajate C, Garayoa M, et al. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res. 2008;68:5216–25.

    Article  CAS  Google Scholar 

  18. Mattioli M, Agnelli L, Fabris S, Baldini L, Morabito F, Bicciato S, et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene. 2005;24:2461–73.

    Article  CAS  Google Scholar 

  19. Agnelli L, Mosca L, Fabris S, Lionetti M, Andronache A, Kwee I, et al. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer. 2009;48:603–14.

    Article  CAS  Google Scholar 

  20. Popovici V, Chen W, Gallas BG, Hatzis C, Shi W, Samuelson FW, et al. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res. 2010;12:R5.

    Article  Google Scholar 

  21. Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol. 2010;28:827–38.

    Article  CAS  Google Scholar 

  22. Mitchell JS, Li N, Weinhold N, Forsti A, Ali M, van Duin M, et al. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun. 2016;7:12050.

    Article  CAS  Google Scholar 

  23. Neves H, Kwok HF. In sickness and in health: the many roles of the minichromosome maintenance proteins. Biochim Biophys Acta Rev Cancer. 2017;1868:295–308.

    Article  CAS  Google Scholar 

  24. Wang J, Jiang W, Yan Y, Chen C, Yu Y, Wang B, et al. Knockdown of EWSR1/FLI1 expression alters the transcriptome of Ewing sarcoma cells in vitro. J Bone Oncol. 2016;5:153–8.

    Article  Google Scholar 

  25. Liu Z, Li J, Chen J, Shan Q, Dai H, Xie H, et al. MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression. BMC Cancer. 2018;18:200.

    Article  Google Scholar 

  26. Cai L, Zhao K, Yuan X. Expression of minichromosome maintenance 8 in chronic myelogenous leukemia. Int J Clin Exp Pathol. 2015;8:14180–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Liu Z, Yang Z, Jiang S, Zou Q, Yuan Y, Li J, et al. MCM2 and TIP30 are prognostic markers in squamous cell/adenosquamous carcinoma and adenocarcinoma of the gallbladder. Mol Med Rep. 2016;14:4581–92.

    Article  CAS  Google Scholar 

  28. Yang J, Ramnath N, Moysich KB, Asch HL, Swede H, Alrawi SJ, et al. Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer. BMC Cancer. 2006;6:203.

    Article  Google Scholar 

  29. Li S, Wang C, Wang W, Liu W, Zhang G. Abnormally high expression of POLD1, MCM2, and PLK4 promotes relapse of acute lymphoblastic leukemia. Medicine (Baltimore). 2018;97:e10734.

    Article  CAS  Google Scholar 

  30. Yousef EM, Furrer D, Laperriere DL, Tahir MR, Mader S, Diorio C, et al. MCM2: an alternative to Ki-67 for measuring breast cancer cell proliferation. Mod Pathol. 2017;30:682–97.

    Article  CAS  Google Scholar 

  31. Dudderidge TJ, Stoeber K, Loddo M, Atkinson G, Fanshawe T, Griffiths DF, et al. Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res. 2005;11:2510–7.

    Article  CAS  Google Scholar 

  32. Davies RJ, Freeman A, Morris LS, Bingham S, Dilworth S, Scott I, et al. Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet. 2002;359:1917–9.

    Article  CAS  Google Scholar 

  33. Burger M, Denzinger S, Hartmann A, Wieland WF, Stoehr R, Obermann EC. Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade. Br J Cancer. 2007;96:1711–5.

    Article  CAS  Google Scholar 

  34. Liu Y, He G, Wang Y, Guan X, Pang X, Zhang B. MCM-2 is a therapeutic target of Trichostatin A in colon cancer cells. Toxicol Lett. 2013;221:23–30.

    Article  CAS  Google Scholar 

  35. Xu P, Zhao M, Liu Z, Liu Y, Chen Y, Luo R, et al. Elevated nuclear CCND1 expression confers an unfavorable prognosis for early stage lung adenocarcinoma patients. Int J Clin Exp Pathol. 2015;8:15887–94.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Bergsagel PL, Mateos M-V, Gutierrez NC, Rajkumar SV, San Miguel JF. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood. 2013;121:884–92.

    Article  CAS  Google Scholar 

Download references

Funding

This work was supported by grants from Xinjiang Joint Fund of National Natural Science Foundation of China (U1903117) and the National Natural Science Foundation of China (81500118) to LF.

Author information

Author notes

  1. These authors contributed equally: Liang Quan, Tingting Qian

Authors and Affiliations

  1. Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, 510260, Guangzhou, China

    Liang Quan, Tingting Qian & Lin Fu

  2. Translational Medicine Center, State Key Laboratory of Respiratory Disease, The Second Affiliated Hospital of Guangzhou Medical University, 510260, Guangzhou, China

    Liang Quan, Tingting Qian & Lin Fu

  3. Translational Medicine Center, Huaihe Hospital of Henan University, 475000, Kaifeng, China

    Longzhen Cui, Yan Liu & Lin Fu

  4. Department of Hematology, Huaihe Hospital of Henan University, 475000, Kaifeng, China

    Longzhen Cui, Yan Liu & Lin Fu

  5. Department of Operations and Information Management, China-Japan Friendship Hospital, 100029, Beijing, China

    Chaozeng Si

Authors
  1. Liang Quan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tingting Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Longzhen Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lin Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chaozeng Si
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LF and CS designed the study. LQ wrote the manuscript. LQ and TQ performed statistical analyses. LC and YL contributed toward revising the paper, and all authors agreed to be accountable for all aspects of the work.

Corresponding authors

Correspondence to Lin Fu or Chaozeng Si.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Quan, L., Qian, T., Cui, L. et al. Prognostic role of minichromosome maintenance family in multiple myeloma. Cancer Gene Ther 27, 819–829 (2020). https://doi.org/10.1038/s41417-020-0162-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41417-020-0162-2

Search

Advanced search

Quick links